An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Antitumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine) Associated With RCHOP Chemotherapy and Rituximab (MabThera) Maintenance in Patients With First-line Advanced Follicular Non Hodgkin's Lymphoma

Trial Profile

An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Antitumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine) Associated With RCHOP Chemotherapy and Rituximab (MabThera) Maintenance in Patients With First-line Advanced Follicular Non Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Sargramostim; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 24 Mar 2012 Actual initiation date (19 Sep 2008) added as reported by European Clinical Trials Database.
    • 24 Mar 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
    • 13 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top